Blood pressure–lowering therapy reduces left ventricular mass, but the question of whether
differences exist among drug classes has not been fully resolved. Our aim was to compare …

Summary Abstract Telmisartan (Micardis®, Pritor®), a highly selective angiotensin II (AII)
type 1 (AT 1) receptor antagonist, is approved for the treatment of hypertension, either as …

Objectives: The purpose of this study was to evaluate the antihypertensive efficacy of
hydrochlorothiazide (HCTZ) by ambulatory blood pressure (BP) monitoring. Background …

Background: The hypothesis that left ventricular hypertrophy regression in hypertension
relates to blood pressure (BP) control and to non-antihypertensive activity of some drugs …

Left ventricular hypertrophy (LVH) induced by systemic hypertension (SH) represents a
maladaptive response to the increased overload. It is known that the LV pathological …

Blockade of the renin–angiotensin system is an important approach in managing high blood
pressure, and has increasingly been shown to affect cardiovascular disease processes …

Background: Found in 36–41% of hypertension, elevated left ventricular mass (LVM)
independently predicts cardiovascular events and total mortality. Conversely, drug-induced …

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
(ONTARGET™) showed that the angiotensin II receptor blocker (ARB) telmisartan was as …

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
(ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not …

Advances in modern echocardiography for quantification of cardiac structure and function
have not been translated in clinical trial or practice applications to date. Imaging endpoints …